The remainder of the projects for the immediate future are irrelevant, as the most pivotal point in the company’s history hangs on the results of this trial.
Is that a bad situation? Yea.
B has proven itself effective in multiple indications, and still could be a platform drug, yet here we sit, waiting for results on a recent virus; a very focal (regardless of global spread) therapeutic need.
Hoping for positive results, as I don’t think the company survives a negative result, and another company will pick up B for chump change- ala polymedix